References
- Adams G.E., Stratford I.J., Nethersell A.B.W. Manipulation of the oxygenation status of tumours: Activation of bioreductive drugs. British Journal of Radiology Report 1989; 19: 71–75
- Bremner J.C.M., Stratford I.J., Bowler J., Adams G.E. Bioreductive drugs and the selective induction of tumour hypoxia. British Journal of Cancer 1990; 61: 717–721
- Brown J.M. Exploitation of bioreductive agents with vaso-active drugs. Radiation Research, E.M. Fielden, J.F. Fowler, J.H. Hendry, D. Scott. Taylor & Francis, London 1987; 2: 719–724
- Chaplin D.J., Acker B. Potentiation of RSU 1069 tumour cytotoxicity by hydralazine: a new approach to selective therapy. International Journal of Radiation Oncology, Biology and Physics 1987; 13: 579–586
- Cole S., Stratford I.J., Adams G.E. Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU 1069. International Journal of Radiation Biology 1989; 56: 587–591
- Edwards H.S., Bremner J.C.M., Stratford I.J. Induction of hypoxia in the KHT sarcoma by Tumour Necrosis Factor and Flavone Acetic Acid. International Journal of Radiation Biology 1991; 59: 419–432
- Murray J.C., Smith K.A., Thurston G. Flavone acetic acid induces coagulopathy in mice. British Journal of Cancer 1989; 60: 729–733
- Sheldon P.W., Hill S.A. Hypoxic cell radiosensitisers and local control by X-ray of a transplanted tumour in mice. British Journal of Cancer 1977; 35: 795–808
- Stratford I.J., Adams G.E., Godden J., Howells N. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. International Journal of Radiation Biology 1989; 55: 411–422
- Sun J., Brown J.M. The bioreductive drug SR 4233 enhances the anti-tumour effect of flavone acetic acid. Cancer Research 1989; 49: 5664–5670